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Prognostic value of blastocyst grade
after frozen euploid embryo transfer
in patients with recurrent
pregnancy loss
Gayathree Murugappan, M.D.,a Julia G. Kim, M.D.,b,c Jonathan D. Kort, M.D.,d Brent M. Hanson, M.D.,b,c
Shelby A. Neal, M.D.,b,c Ashley W. Tiegs, M.D.,b,c Emily K. Osman, M.D.,b,c Richard T. Scott, M.D.,b,c
and Ruth B. Lathi, M.D.a
a

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University,
Sunnyvale, California; b IVI/Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey; c Division of
Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College,
Thomas Jefferson University, Philadelphia, Pennsylvania; and d IVI/Reproductive Medicine Associates of Northern
California, Palo Alto, California

Objective: To determine whether trophectoderm (TE) grade or inner cell mass (ICM) grade have predictive value after euploid frozen
embryo transfer (euFET) among recurrent pregnancy loss (RPL) patients.
Design: Retrospective cohort study.
Setting: Single fertility center.
Patient(s): Women with R2 prior pregnancy losses with R1 euploid embryo for transfer undergoing preimplantation genetic testing
for aneuploidy.
Intervention(s): Intracytoplasmic sperm injection, TE biopsy, blastocyst grading and vitriﬁcation, and single euFET, with ﬁrst transfer
outcome recorded.
Main Outcome Measure(s): Live birth and clinical miscarriage rates.
Result(s): The study included 660 euFET cycles. In a binomial logistic regression analysis accounting for age, body mass index,
antim€
ullerian hormone level, and day of blastocyst biopsy, or ICM grade C was not signiﬁcantly associated with odds of live birth,
miscarriage, or biochemical pregnancy loss. TE grade C was signiﬁcantly associated with odds of live birth and was not associated
with odds of miscarriage or biochemical pregnancy loss. Blastocyst grade CC had signiﬁcantly lower live birth rate compared with
all other blastocyst grades.
Conclusion(s): Embryo grade CC and TE grade C are associated with decreased odds of live birth after euFET in RPL patients. Embryo
grade is not associated with odds of clinical miscarriage in this cohort of RPL patients, suggesting that additional embryonic or uterine
factors may inﬂuence the risk of pregnancy loss. (Fertil Steril RepÒ 2020;1:113–8. Ó2020 by American Society for Reproductive
Medicine.)
Key Words: Embryo grade, euploid transfer, miscarriage, PGT-A, recurrent pregnancy loss
Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertilityand-sterility/posts/xfre-d-20-00090

M

anagement of patients with
recurrent pregnancy loss
(RPL) continues to be a

challenge for clinicians. The role of
aneuploidy in miscarriage is well documented, with over 50% of pregnancy
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losses attributed to fetal chromosomal
abnormalities and even higher aneuploidy rates reported among older patients (1, 2). Due to the prevalence of
aneuploidy in ﬁrst-trimester losses
and in the RPL population, preimplantation genetic testing for aneuploidy
(PGT-A) has been used as a method
for reducing miscarriage by selecting
only euploid embryos for transfer (3,
4). Causes of euploid miscarriage,
particularly in the setting of RPL,
remain a topic of great interest to
113
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both physicians and patients. In the absence of an explanation, patients often seek unproven testing and treatments.
The current literature on the prognostic value of blastocyst assessment applies to the general infertile population.
Blastocyst morphological grading was ﬁrst described by
Gardner et al. (5). Since then, studies have teased apart the
relative contribution of trophectoderm (TE) and inner cell
mass (ICM) grade on an embryo’s potential to implant and
result in a live birth. After transfer of untested blastocysts,
TE grade has been shown to be a superior predictor of live
birth in fresh cycles (6, 7) and a superior predictor of live birth
and miscarriage in frozen cycles (8). Embryo morphology,
however, is not consistently correlated with euploidy.
Both ICM and TE grades have been reported by Capalbo
et al. (9) to be unrelated to implantation outcomes after frozen
euploid embryo transfer (euFET), but only 13 embryos were
included in the poor-quality blastocyst group. Conﬂicting results have subsequently been published using the same classiﬁcation scheme but with a larger comparison group of
106 poor-quality euploid embryos. In the latter study, Irani
et al. (10) reported an approximately twofold higher pregnancy rate and 25-fold lower miscarriage rate among
excellent-quality euploid blastocysts compared with poorquality euploid blastocysts and that ICM morphology is a better predictor of pregnancy outcomes than TE morphology
(10). A large study by Zhao et al. (11) showed similar predictive value of TE and ICM grades in pregnancy outcomes after
euFET. Our study examined whether TE grade or ICM grade
retained their established predictive values after euFET in a
cohort of RPL patients.

MATERIALS AND METHODS
Patient selection

Patients with RPL having PGT-A performed with at least one
euploid embryo for transfer from 2012–2018 were included in
the study. We deﬁned RPL as two or more prior pregnancy losses, inclusive of biochemical conceptions but independent of
other infertility diagnoses. All patients had a complete RPL
workup as recommended by the American Society for Reproductive Medicine (ASRM), including bloodwork for parental
karyotypes and to detect the presence of antiphospholipid antibody syndrome (APLA) including anticardiolipin antibody,
lupus anticoagulant, and b2-glycoprotein, as well as a uterine
cavity evaluation. Patients were also routinely screened for hypothyroidism and hyperprolactinemia with serum thyroidstimulating hormone and prolactin, respectively. Patients
who were known to be translocation carriers (either maternal
or paternal) were excluded. Patients with the APLA syndrome
were offered low-dose aspirin and prophylactic heparin. Patients with uterine cavity anomalies, including a uterine
septum, intramural ﬁbroids, or uterine polyps, underwent hysteroscopy and transection of the uterine septum, myomectomy,
or polypectomy, respectively, before embryo transfer.

Clinical protocols
Controlled ovarian hyperstimulation was performed
according to standard protocols per physician discretion.
114

The stimulation protocols included microdose ﬂare, Lupron
down-regulation, gonadotropin-releasing hormone antagonist, and natural cycle. After transvaginal oocyte retrieval,
all oocytes were fertilized with intracytoplasmic sperm injection, and all blastocysts underwent TE biopsy on day 5, 6, or 7
of embryo development once full expansion had been
achieved. All embryos were vitriﬁed after TE biopsy. Embryos
were graded at the time of cryopreservation using the Gardner
grading scale. We implemented PGT-A using next-generation
sequencing (NGS), quantitative reverse-transcription polymerase chain reaction (qRT-PCR), or array comparative
genomic hybridization platforms. All patients underwent
frozen transfer of a single euploid blastocyst.
The endometrial lining was prepared using modiﬁed natural cycle or medicated cycle protocols per physician discretion. For natural cycles, patients used vaginal progesterone
suppositories for luteal support until 8 weeks’ gestational
age. For medicated cycles, the endometrium was primed
with oral estradiol, estrogen patches, or intramuscular estrogen valerate, and luteal support was provided through intramuscular progesterone in oil until 8 weeks’ gestational age, at
which time support was transitioned to vaginal suppositories
until 10 weeks.
Blastocyst transfer took place on the sixth day after human chorionic gonadotropin (hCG) administration in modiﬁed natural cycles, and on day 6 of progesterone
supplementation in programmed cycles. Embryo transfers
were performed with transabdominal ultrasound guidance after conﬁrmation of embryo survival after warming. The serum
progesterone level was measured 2 days after transfer, and the
serum hCG level was obtained 9 days after transfer. Transvaginal ultrasound to monitor for the presence of a gestational
sac was performed during the ﬁfth week of gestation, with
subsequent pregnancy ultrasounds to monitor the fetal heart
rate and appropriate growth between 6 to 8 weeks’ gestation.
The outcome of the ﬁrst euFET was recorded.

Outcome variables
The main outcome measured was live birth, deﬁned as birth of
a neonate at or beyond 24 weeks’ gestation. The secondary
outcome was clinical miscarriage, deﬁned as loss of pregnancy after visualization of a gestational sac on ultrasound.
Additional outcomes measured included implantation
(deﬁned as b-hCG >5 mIU/mL), clinical pregnancy (deﬁned
as b-hCG >5 mIU/mL and a visualized gestational sac), and
biochemical pregnancy loss (deﬁned as loss of pregnancy after conception, b-hCG level >5 mIU/mL, and before visualization of a gestational sac on transvaginal ultrasound).
Implantation, clinical pregnancy, and live birth were calculated per embryo transfer. Biochemical pregnancy loss rate
was calculated per implantation. Clinical miscarriage rate
was calculated per clinical pregnancy.

Statistical analysis
The baseline parameters of the patients were compared using t
tests or single factor analysis of variance. Chi-square analysis
was performed to compare the proportion of assisted
VOL. 1 NO. 2 / SEPTEMBER 2020
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reproduction outcomes within each morphologic grade. We
modeled the association between TE grade or ICM grade (A,
B, or C, with A as reference) and pregnancy outcome (live
birth, clinical miscarriage, or biochemical pregnancy loss) after euFET using logistic regression. The model was adjusted
for age (continuous), body mass index (BMI; categorical subullerian
divided as BMI R25 kg/m2 or BMI <25 kg/m2), antim€
hormone level (AMH; categorical subdivided as AMH <1 ng/
mL or R1 ng/mL), and day of blastocyst biopsy (day 5, 6, or
7). We included AMH level as a covariate in our analysis
because it has been shown to be a predictor of live-birth
rate in RPL patients overall (12); also RPL patients with
AMH <1 ng/mL have a higher percentage of aneuploid blastocysts (13). Statistical analysis was performed using SPSS
software version 25 (IBM, Inc.). P< .05 was considered statistically signiﬁcant. This study was exempt from institutional
review board approval because it was a retrospective analysis
of deidentiﬁed data.

RESULTS
We included 660 euFET cycles in the analysis. The average patient age was 36.7  3.4 years, average BMI was 25.7  5.6
kg/m2, and patients had on average 3.5  1.5 prior pregnancies, 0.5  0.8 term deliveries, and 2.6  1.1 prior pregnancy
losses. The average AMH level was 3.4  3.8 ng/mL and
average FSH level was 7.5  2.8 IU/mL before stimulation
start. Patients with TE grade C (average age 38.3 years) were
statistically signiﬁcantly older than the patients with TE grade
B (average age 37.2 years; P¼ .02) and patients with TE grade
A (average age 36.5 years, P< .05). Patients with TE grade C
had an average AMH level (3.4  3.8 ng/mL) similar to the patients with TE grade B (average AMH, P¼ .95) and patients
with TE grade A (average AMH 3.9  4.5 ng/mL; P¼ .10). Patients with TE grades A, B, and C had a similar BMI (P¼ .80).
Patients with ICM grade C (average age 37.5 years) were statistically signiﬁcantly older than patients with ICM grade A
(average age 36.0 years; P¼ .01) and similar in age to patients
with ICM grade B (average age 37.0 years; P¼ .43). Patients
with ICM grade A, B, and C had similar BMI (P¼ .55). Patients
with embryo grade CC were on average 37.0  4.3 years of age
with AMH 2.7  2.4 ng/mL. Compared with the overall
cohort, these patients did not differ in terms of age (P¼ .69)
or AMH level (P¼ .52).
For controlled ovarian hyperstimulation, 82% of cycles
used an antagonist protocol, 11% of cycles used a microdose
ﬂare protocol, 6% used a long Lupron protocol, and 1% used a
natural cycle. For PGT-A, 54% were performed using a qRTPCR platform, 45% used NGS, and a microarray platform was
used for 1% of cycles. On average per oocyte retrieval, 15.5 
9.8 oocytes were retrieved, 5.4  3.8 blastocysts were biopsied
for PGT-A, and 3.6  2.9 embryos were euploid. Patients with
TE grade C had on average per oocyte retrieval 11.1  7.8 oocytes retrieved, 2.6  1.7 embryos biopsied, and 1.4  0.9
euploid embryos.
Compared with patients with TE grades A and B, patients with TE grade C had fewer oocytes retrieved
(P< .01), fewer embryos biopsied (P< .01) and fewer euploid
embryos (P< .01). Patients with embryo grade CC had on
VOL. 1 NO. 2 / SEPTEMBER 2020

average per oocyte retrieval 11.0  5.8 oocytes retrieved,
2.4  1.6 embryos biopsied, and 1.5  1.0 euploid embryos.
Compared with the overall cohort, patients with embryo
grade CC did not differ in terms of number of oocytes
retrieved (P¼ .06) but had statistically signiﬁcantly fewer
embryos biopsied (P%.01) and fewer number of euploid embryos (P%.01).
The endometrial lining was prepared before transfer by
use of a medicated cycle for 78% of transfers and a natural cycle protocol for the remaining cycles (22%). The average
endometrial thickness before embryo transfer was 9.4  2.1
mm. The overall live-birth rate per euFET was 62% (n ¼ 408).
The clinical outcomes stratiﬁed by ICM and TE grade are
shown in Table 1. There were 217 ICM grade A euFETs, 405
ICM grade B euFETs, and 38 ICM grade C euFETs. The live
birth, clinical miscarriage, and biochemical pregnancy loss
rates were similar for ICM grades A, B, and C (P¼ .08,
P¼ .38, and P¼ .45, respectively, chi-square analysis). In a logistic regression analysis accounting for age, BMI, AMH, and
day of blastocyst biopsy, ICM grade B was not statistically
signiﬁcantly associated with odds of live birth (adjusted
odds ratio [aOR] 0.80; 95% conﬁdence interval [CI] 0.56–
1.14; P¼ .21), miscarriage (aOR 1.53; 95% CI 0.85–2.77;
P¼ .16), or biochemical pregnancy loss (aOR 0.87; 95% CI
0.47–1.62; P¼ .66) (Table 2). Also ICM grade C was not statistically signiﬁcantly associated with odds of live birth (aOR
0.50; 95% CI 0.24–1.02; P¼ .057), miscarriage (aOR 1.67;
95% CI 0.56–5.00; P¼ .36), or biochemical pregnancy loss
(aOR 1.58; 95% CI 0.53–4.75; P¼ .42).
There were 312 TE grade A euFETs, 277 TE grade B euFETs, and 71 TE grade C euFETs. The live-birth rates for TE
grades A, B, and C differed statistically signiﬁcantly by chisquare analysis (P¼ .01) whereas the clinical miscarriage
and biochemical pregnancy loss rates were similar (P¼ .25
and P¼ .37, respectively, chi-square analysis). In a logistic
regression analysis accounting for age, BMI, AMH, and day
of blastocyst biopsy, TE grade B was not associated with
odds of live birth (aOR 0.90; 95% CI 0.63–1.27; P¼ .53),
miscarriage (aOR 1.37; 95% CI 0.79–2.39; P¼ .27), or
biochemical pregnancy loss (aOR 1.08; 95% CI 0.58–2.00;
P¼ .82). Trophectoderm grade C was statistically signiﬁcantly
associated with odds of live birth (aOR 0.49; 95% CI 0.28–
0.86; P¼ .01) and was not associated with odds of miscarriage
(aOR 2.00; 95% CI 0.89–4.47; P¼ .09) or biochemical pregnancy loss (aOR 1.85; 95% CI, 0.77–4.44; P¼ .17).
Live-birth outcomes for embryos with combined ICM and
TE grades AA, AB, BA, BB, BC, CA, CB, and CC are shown in
Figure 1. Sixteen blastocysts were grade CC, with an implantation rate of 69% (n ¼ 11), clinical pregnancy rate of 50% (n
¼ 8), live-birth rate of 31% (n ¼ 5), clinical miscarriage rate of
38% (n ¼ 3), and biochemical loss rate of 27% (n ¼ 3). Blastocyst grade CC had a statistically signiﬁcantly lower livebirth rate compared with all other blastocyst grades: AA,
AB, BA, BB, BC, and CB (P< .05, chi-square analysis).

DISCUSSION
In this cohort of RPL patients, we report that TE grade C and
blastocyst grade CC are associated with a statistically
115
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TABLE 1
Comparison of outcomes after euploid frozen embryo transfer stratiﬁed by inner cell mass and trophectoderm blastocyst grades.
Clinical
Clinical
Biochemical
Grade euFET (n) Implantationa P valueb pregnancyc P valueb Live birthd P valueb miscarriagee P valueb pregnancy lossf P valueb
ICM
A
B
C
TE
A
B
C

217
405
38

185 (85)
327 (81)
29 (81)

.24

164 (76)
293 (72)
24 (63)

.26

145 (67)
244 (60)
19 (50)

.08

18 (11)
47 (16)
5 (21)

.38

19 (10)
31 (9)
5 (17)

.45

312
277
71

259 (83)
228 (82)
54 (76)

.38

232 (74)
205 (75)
44 (62)

.09

203 (65)
172 (62)
33 (46)

.01

28 (12)
31 (15)
11 (25)

.25

24 (9)
22 (10)
9 (17)

.37

Note: Values are number (percentage) unless speciﬁed otherwise. euFET ¼ euploid frozen embryo transfer; ICM ¼ inner cell mass; TE ¼ trophectoderm.
a
Implantation was deﬁned as b-human chorionic gonadotropin level > 5 mIU/mL.
b
Chi-square analysis.
c
Clinical pregnancy was deﬁned as a visualized gestational sac.
d
Live birth was deﬁned as delivery of a neonate at or beyond 24 weeks.
e
Clinical miscarriage rate was calculated per clinical pregnancy.
f
Biochemical pregnancy loss was deﬁned as loss of pregnancy after conception and before visualization of a gestational sac on transvaginal ultrasound. Biochemical pregnancy loss rate was calculated per implantation.
Murugappan. Blastocyst grade and pregnancy outcome in RPL. Fertil Steril Rep 2020.

signiﬁcant decrease in odds of live birth after euFET. After the
transfer of untested blastocysts in general infertile cohorts, TE
grade has been shown to be a superior predictor of live birth in
fresh cycles (6, 7) and a superior predictor of live birth and
miscarriage in frozen cycles (8).To our knowledge, ours is
the ﬁrst report on the association of embryo grade and outcomes in RPL patients undergoing euFET, and our data support the previous reports that blastocyst morphology is
associated with live-birth outcome after euFET (10, 11).
In any patient population, myriad factors inﬂuence
reproductive outcomes. Among RPL patients in whom additional factors may impact outcomes, it is notable that blastocyst morphology retains its predictive value for live birth. The
association, if any, between embryo grade and pregnancy loss
is particularly interesting in the RPL patient population. Irani
et al. (10) reported a striking trend among euFET cycles in a

general infertile cohort, with a 25% miscarriage rate after
frozen transfer of poor-quality euploid blastocysts (n ¼ 51)
compared with no miscarriages after frozen transfer of
excellent-quality euploid blastocysts (n ¼ 32) and a 6%
miscarriage rate after frozen transfer of good-quality euploid
blastocysts (n ¼ 50). Patients with RPL are at higher risk of
euploid miscarriage (14), and the varying contributions of
embryonic and uterine factors are unknown.
In our study, when comparing outcomes for embryos with
ICM or TE grade C compared with higher grades, there was a
trend toward higher risk of miscarriage with poorer embryo
grade, but the differences were not statistically signiﬁcant.
This ﬁnding is likely multifactorial, due in part to the small
size of the subgroups, but also may suggest that there is additional variability in reproductive efﬁciency among RPL patients that is not captured by euploidy or blastocyst

TABLE 2
Association between inner cell mass or trophectoderm grade and pregnancy outcome after euploid frozen embryo transfer.
Outcome

Crude OR (95% CI)

P value

Adjusted OR (95% CI)a

P value

0.75 (0.53–1.06)
1.12 (0.42–3.02)
0.87 (0.48–1.57)

.10
.82
.64

0.80 (0.56–1.14)
1.53 (0.85–2.77)
0.87 (0.47–1.62)

.21
.16
.66

0.86 (0.62–1.21)
1.33 (0.78–2.27)
1.04 (0.57–1.90)

.38
.30
.90

0.90 (0.63–1.27)
1.37 (0.79–2.39)
1.08 (0.58–2.00)

.53
.27
.82

0.45 (0.22–0.90)
1.68 (0.58–4.82)
1.58 (0.55–4.52)

.02
.34
.40

0.50 (0.24–1.02)
1.67 (0.56–5.00)
1.58 (0.53–4.75)

.057
.36
.42

0.47 (0.28–0.79)
1.86 (0.88–3.94)
1.74 (0.77–3.93)

.004
.11
.18

0.49 (0.28–0.86)
2.00 (0.89–4.47)
1.85 (0.77–4.44)

.01
.09
.17

b

ICM grade B
Live birth
Clinical miscarriage
Biochemical pregnancy loss
TE grade Bb
Live birth
Clinical miscarriage
Biochemical pregnancy loss
ICM grade Cb
Live birth
Clinical miscarriage
Biochemical pregnancy loss
TE grade Cb
Live birth
Clinical miscarriage
Biochemical pregnancy loss

Note: AMH ¼ antim€
ullerian hormone; BMI ¼ body mass index; CI ¼ conﬁdence interval; ICM ¼ inner cell mass; OR ¼ odds ratio; TE ¼ trophectoderm.
a
Adjusted for age (continuous), overweight (categorical, BMI R25 kg/m2 or BMI <25 kg/m2), AMH (categorical, <1 ng/mL or R1 ng/mL), and day of blastocyst biopsy (5, 6, or 7).
b
Logistic regression model, ICM or TE grade A used as reference.
Murugappan. Blastocyst grade and pregnancy outcome in RPL. Fertil Steril Rep 2020.
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FIGURE 1

Comparison of live birth rate per patient after euploid frozen embryo transfer stratiﬁed by combined inner cell mass (ICM)/ trophectoderm (TE)
blastocyst grades. Results not shown in graph: one grade CA embryo was transferred, resulting in implantation and subsequent miscarriage.
*P<.05, chi-square analysis.
Murugappan. Blastocyst grade and pregnancy outcome in RPL. Fertil Steril Rep 2020.

morphology. The parameters that affect outcomes in a general
infertile population may be less predictive among RPL patients, in whom uterine factors that are not accounted for or
embryo factors that are yet to be understood may play an
important role in miscarriage. This information can be used
as an aid to counsel RPL patients on risk of miscarriage after
euploid transfer.
The strengths of this study include a relatively large sample size for studying an RPL population and use of single blastocyst euploid frozen transfer for all patients to minimize
confounding due to number of embryos transferred and the
effect of freeze/thaw cycles on the TE or ICM. A limitation
of the study, as previously noted in the literature, is the intraand interobserver variability in embryo grading (15, 16). Our
results, however, are from a single center with regular proﬁciency and consistency checks. Because our outcome was
limited to a single-embryo transfer, we were not able to identify overall egg or sperm quality. Furthermore, our analysis
was limited to patients reaching transfer of at least a CC grade
or higher quality euploid embryo, which may not be reﬂective
of outcomes in poorer prognosis cycles. In addition, our ﬁndings may not be applicable to an unscreened population of
embryos because morphologic assessment was only performed on the embryos designated as being of sufﬁcient quality to merit cryopreservation.
Although all RPL patients underwent a complete evaluation per ASRM guidelines, and all patients with translocations
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were excluded, the granular data on the number of patients
who received treatment for APLA or correction of uterine
anomalies was not available and may present unmeasured
confounding. As this study focused exclusively on patients
with RPL, our ﬁndings cannot be used to differentiate the
prognostic value of the embryos from other subgroups of patients. Our ﬁndings are, however, supported by prior studies in
a general infertile population (10, 11).
Different PGT-A platforms were used for this study,
which introduces heterogeneity and potential for unmeasured confounding of study results. However, qRT-PCR,
NGS, and array comparative genomic hybridization have
been validated for use through large, prospective randomized clinical studies (17–19). In addition, many studies
examining PGT-A are similarly limited by heterogeneity
of testing methodology such that ASRM does not endorse
one testing platform in particular (20). Also, although day7 blastocysts have been associated with lower pregnancy
and live-birth rates and could bias study results (21–24),
of the 660 cycles included in this study, only four
(0.6%) performed TE biopsy on day 7.
Finally, the results are limited by the relatively small
number of poorer quality embryos. The lack of difference in
clinical outcomes between various embryo grades may be
due to limited statistical power. Larger scale, prospective analyses accounting for total cycle potential are warranted to
conﬁrm the reported ﬁndings.
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CONCLUSION
Association between embryo grade and clinical outcomes had
not been previously been reported in RPL patients. Embryo
grade CC and TE grade C are associated with a statistically signiﬁcant decrease in odds of live birth after euFET in RPL patients. Furthermore, embryo grade was not predictive of
clinical miscarriage rate in this cohort of RPL patients, suggesting that additional embryonic or uterine factors may inﬂuence their risk of pregnancy loss.
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